An association between renal cell carcinoma and multiple myeloma: A case series and clinical implications

BJU International

Volumn 101, Issue 6, 2008, Pages 712-715

  Choueiri, Toni K ^a   Baz, Rachid C ^b   McFadden, Carolyn M ^b   Khasawneh, Mohamad ^b   Karam, Mary Ann ^b   Kelly, Megan ^b   Hussein, Mohamad A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Expected incidence; Multiple myeloma; Renal cell carcinoma; Renal mass

Indexed keywords

ARSENIC TRIOXIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE LESION; CANCER PATIENT; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; FEMALE; FISHER EXACT TEST; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; INCIDENCE; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39449127415     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07268.x     Document Type: Article

References (10)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 : 106 30
2. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004 10 : 6290S 5S
3. Sakai A, Kawano M, Kuramoto A. Interleukin-6 produced by renal-cell carcinoma cells and progression of multiple myeloma. N Engl J Med 1991 324 : 1893 4
4. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer. a review of the rationale and clinical evidence. Clin Cancer Res 2003 9 : 4653 65
5. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 17 : 2530 40
6. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005 23 : 832 41
7. http://www.thalomid.com/pdf/Thalomid_Pl.pdf. Accessed 3 September 2007
8. McDougal WS, Cramer SF, Miller R. Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease. Cancer 1981 48 : 691 5
9. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994 7 : 85 90
10. Anglard P, Tory K, Brauch H et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991 51 : 1071 7